GlaxoSmithKline (GSK) The company’s current corporate strategy includes a major focus on the Emerging Markets and Asia Pacific (EMAP) region. Concretely, what are the expectations and the main objectives for the Asia Pacific region? GSK Asia Pacific is composed of: North East Asia, South East Asia and South Pacific (this includes countries…
ireland Mr. Mazeman, can you please begin by offering a brief overview of your career to date? I am a French pharmacist by training, with expertise in pharmacology. I have worked for Servier for my entire career. I started in the industry as a medical representative for the company. I went…
Eurogentec Belgium Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the business model of the life sciences industry? The pharmaceutical industry is increasingly being under pressure by the rising costs of…
Medicines Australia We last met you in 2008 as Chair of the Pharmaceuticals Industry Council (PIC), which set itself the goal of doubling the levels of exports, R&D investment, manufacturing, value-added activities, and clinical trials from 2002 to 2012. Are you content looking at the achievements today? Exports still stand at about…
Department of Industry Would you outline the commitment of the Ministry to foster a positive business environment for the Australian pharmaceutical industry to prosper? Issues faced by the pharmaceutical industry are not unlike those in many other industries and the high value of our dollar has brought a sharp focus to industry productivity…
Baxter Mexico Baxter established itself in Mexico as early as 1948 through the acquisition of a local manufacturer, Madom’s Pharmaceutical. In a vast market like France, operations started 40 years ago; in Chile, operations started only in 1995; how do you explain the very early focus on Mexico? Mexico has always been…
market You established Menarini’s Irish affiliate in 1999. How have you seen the market evolve over these last 13 years? The major changes in the market have principally occurred in the last four or five years, rather than the previous ten. Generally speaking, the industry has always had a very strong…
Department of Health & Ageing You were appointed last year with a specialized portfolio reflecting some of the key priorities on the country’s health care agenda. Would you begin by outlining your mission for your tenure? Prime Minister Gillard announced during the last election in 2010 that both mental health reform and aged care reform…
Boehringer Ingelheim Benelux Can you illustrate to our readers the company’s main milestones and key achievements since you took the reins four years ago? In the last years we have experienced a period of strong growth for the company based on the portfolio which we had. Today, however, following a strong focus on…
MSD In Q3 2012, MSD reported worldwide sales of $11.5 billion. What was the contribution that emerging markets had? From an MSD perspective, emerging markets refer to every market outside North America, Western Europe and Japan. Today, emerging markets contribute to around 18% of MSD’s total revenues. For the next 5…
Albany Molecular Research Prior to joining AMRI you worked in diverse companies in Japan, like Dishman, Pfizer and Bayer. What attracted you to this company? The main reason is that Singapore has growing opportunities in drug discovery. I worked for a few years in business development with Dishman and although I enjoyed this…
TiGenix - Belgium Mr Bravo, in relation to your previous career in big pharma companies, you have recently made a shift into much smaller entities including Cellerix and TiGenix. What motivated you to make such a dramatic and bold shift in your professional life? I was young and ambitious and despite having a…
See our Cookie Privacy Policy Here
